Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #12 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Alkem Laboratories Limited (this stock) | 62,084 | 29.1 | 16.4% | -5.5% | 1.02% | 85 | 34 | 47 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 3,740 | 772 | 521 | ₹ |
| March 31, 2026 | 3,603 | 423 | 251 | ₹ |
| Dec. 31, 2025 | 3,737 | 781 | 653 | ₹ |
| Sept. 30, 2025 | 4,001 | 896 | 779 | ₹ |
| June 30, 2025 | 3,371 | 771 | 668 | ₹ |
| March 31, 2025 | 3,144 | 396 | 322 | ₹ |
| Dec. 31, 2024 | 3,374 | 731 | 641 | ₹ |
| Sept. 30, 2024 | 3,415 | 780 | 702 | ₹ |
| June 30, 2024 | 3,032 | 619 | 550 | ₹ |
| March 31, 2024 | 2,936 | 367 | 304 | ₹ |
| Dec. 31, 2023 | 3,324 | 655 | 604 | ₹ |
| Sept. 30, 2023 | 3,440 | 648 | 615 | ₹ |
| June 30, 2023 | 2,968 | 353 | 288 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 14,712 | 2,871 | 2,351 |
| March 31, 2025 | 12,965 | 2,527 | 2,215 |
| March 31, 2024 | 12,668 | 2,023 | 1,811 |
| March 31, 2023 | 11,599 | 1,305 | 1,007 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,963 | -1,667 | -503 | 617 | 1,346 |
| March 31, 2025 | 1,913 | -1,299 | -811 | 676 | 1,237 |
| March 31, 2024 | 1,948 | -1,009 | -1,145 | 259 | 1,689 |
| March 31, 2023 | 1,682 | 113 | -1,761 | 233 | 1,450 |
| March 31, 2022 | 1,111 | -1,435 | 380 | 339 | 772 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 20,873 | 14,349 | 13,796 | 1,131 | 492 | 12,211 | 4,783 | 248 | 2,695 | 3,333 |
| March 31, 2025 | 17,691 | 12,434 | 11,961 | 752 | 311 | 10,811 | 3,959 | 304 | 2,064 | 2,922 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
